Stockscreener 앱 받기
2.05
5.09%
-0.11
시간 외 거래:
2.04
-0.010
-0.49%
전일 마감가:
$2.16
열려 있는:
$2.08
하루 거래량:
48,364
Relative Volume:
0.11
시가총액:
$169.71M
수익:
$47.04M
순이익/손실:
$-63.98M
주가수익비율:
-2.5422
EPS:
-0.8064
순현금흐름:
$-34.39M
1주 성능:
-32.12%
1개월 성능:
+21.63%
6개월 성능:
-4.21%
1년 성능:
-23.65%
1일 변동 폭
$2.025
$2.10
1주일 범위
$2.025
$2.67
52주 변동 폭
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.05 | 169.71M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 개시 | Goldman | Neutral |
Innate Pharma Adr 주식(IPHA)의 최신 뉴스
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Innate Pharma S.A. ADR (IPHA-Q) QuotePress Release - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update - The Globe and Mail
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Yahoo Movies UK
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Investing.com India
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr (IPHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):